non-cephalosporin gonorrhea therapies

as perhaps a follow-up to the last blog on pelvic exams, there was a recent article in  Journal of Infectious Diseases looking at non-cephalosporin treatments for gonorrhea (see gonorrhea noncephalosporin rx JID 2104 in dropbox,or doi: 10.1093/cid/ciu521). this article is important because of the increasing resistance of gonorrhea to multiple agents over the past 50 years (eg, sulfa, penicillins, tetracyclines, cipro). at this time the only recommended treatment by the CDC is cephalosporins (eg, ceftriaxone, since there is too much resistance to cefixime), but there are reports of resistance to ceftriaxone, and it is unclear what to do if the patient has significant cephalosporin allergy. hence the importance of this study, where 401 patients (mean age 27, 35% MSM, and only 10% women, 60% black, 22% white, 9% HIV positive), from 5 sites across the US with uncomplicated GC aged 15-60 were randomly assigned to gentamicin 240 mg IM plus azithromycin 2 gm orally, or gemifloxacin (a 4th generation fluoroquinolone) 320mg orally plus azithromycin 2 gm orally. primary outcome was microbiological cure at 10-17 days after treatment. this study was supported by the CDC and NIH. results:



--202 patients receiving gentamicin/azithro: 100% cure, including 10 of 10 pharyngeal infections and 1 of 1 rectal infections
--199 patients receiving gemifloxacin/azithro: 99.5% cure, including 15 of 15 pharyngeal infections and 5 of 5 rectal infections​ (the one patient who failed therapy probably had a reinfection)
--GI adverse effects were common and pretty similar in both groups: 30+% with nausea, 5% with vomiting, 20% with diarrhea -- the vast majority being "mild". somewhat more GI toxicity in the gemifloxacin arm, though probably the GI toxicity is largely from the azithro



so, these may be important therapies in the future. azithro 2gm has good efficacy as monotherapy, but the concern is that gonorrhea develops resistance to macrolides pretty easily.  the above is clearly a preliminary study. there are concerns about the skew of the patients (eg, very few women), and how easily gonorrhea might develop resistance to these meds (though it is heartening that there was a 100% cure rate, and the likelihood of resistance is probably less with double therapy). but this seems pretty reasonable to me for patients either with cephalosporin resistance or intolerance

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

HDL a negative risk factor? or cholesterol efflux??

Although the data on HDL being protective of atherosclerotic disease is pretty consistent, there are negative studies, and the data on medications which dramatically improve HDL levels (eg, the cholesteryl ester transfer protein --CETP --inhibitors, such as torcetrapib) are clinically disappointing. there have been several explanations for this. for example, some HDL particles are "pro-inflammatory" and elicit an atherosclerotic response (which may be related to apolipoprotein C-III). a new article in NEJM highlights another angle -- that the issue is not the HDL number, but HDL's functionality in the reverse transport of cholesterol, as measured by the cholesterol efflux capacity (see  lipids HDL efflux capacity vs amt NEJM 2014 in dropbox, or  DOI: 10.1056/NEJMoa1409065). This article looks at the Dallas Heart Study, where they measured HDL levels, HDL particle concentrations, and cholesterol efflux capacity in 2924 adults free of cardiovascular disease and followed p
Read more

Drug company shenanigans: narcolepsy drug

I have not done a blog for a long time on drug company shenanigans. So it is my great pleasure to bring up a brand-new drug company approach to garner huge amounts of money (see  https://www.nytimes.com/2023/02/28/business/jazz-narcolepsy-avadel-patents.html?smid=nytcore-ios-share&referringSource=articleShare  ).  Based on an article by  Rebecca Robbins of the New York Times, who has written several articles on drug company excesses   As background, this will be my 42 nd  such blog: for the array, see  https://bucommunitymed.wpengine.com/page/4/?s=drug+company+shenanigans   Th e drug company  approach  this time  to extending  their  patents has a few “interesting” angles: -- this is a medication manufactured by Jazz Pharmaceuticals to treat narcolepsy: there are 2 versions: Xyrem and Xywav (Xywav has less sodium, so is marketed to those who should be on a low sodium diet). These meds are basically derivatives of gammahydroxybutyric acid (GHB)      -- the drug actually has a pretty
Read more

UPDATE: ASCVD risk factor critique

  I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:              -- there is very clear evidence that there are many individual risk factors that are associated with increased risk of a cardiovascu
Read more